Long Douglas E, Kosmac Kate, Dungan Cory M, Bamman Marcas M, Peterson Charlotte A, Kern Philip A
Department of Physical Therapy and Center for Muscle Biology, College of Health Sciences, University of Kentucky, Lexington, KY, United States.
Florida Institute for Human and Machine Cognition, Pensacola, FL, United States.
Front Physiol. 2022 Apr 14;13:872745. doi: 10.3389/fphys.2022.872745. eCollection 2022.
Metformin and statins are currently the focus of large clinical trials testing their ability to counter age-associated declines in health, but recent reports suggest that both may negatively affect skeletal muscle response to exercise. However, it has also been suggested that metformin may act as a possible protectant of statin-related muscle symptoms. The potential impact of combined drug use on the hypertrophic response to resistance exercise in healthy older adults has not been described. We present secondary statin analyses of data from the MASTERS trial where metformin blunted the hypertrophy response in healthy participants (>65 years) following 14 weeks of progressive resistance training (PRT) when compared to identical placebo treatment ( = 94). Approximately one-third of MASTERS participants were taking prescribed statins. Combined metformin and statin resulted in rescue of the metformin-mediated impaired growth response to PRT but did not significantly affect strength. Improved muscle fiber growth may be associated with medication-induced increased abundance of CD11b+/CD206+ M2-like macrophages. Sarcopenia is a significant problem with aging and this study identifies a potential interaction between these commonly used drugs which may help prevent metformin-related blunting of the beneficial effects of PRT. ClinicalTrials.gov, NCT02308228, Registered on 25 November 2014.
二甲双胍和他汀类药物目前是大型临床试验的重点，这些试验旨在测试它们对抗与年龄相关的健康衰退的能力，但最近的报告表明，这两种药物都可能对骨骼肌对运动的反应产生负面影响。然而，也有人提出二甲双胍可能是他汀类药物相关肌肉症状的一种潜在保护剂。联合用药对健康老年人抗阻运动肥大反应的潜在影响尚未见描述。我们对MASTERS试验的数据进行了他汀类药物的二次分析，在该试验中，与相同的安慰剂治疗相比（n = 94），二甲双胍减弱了健康参与者（>65岁）在进行14周渐进性抗阻训练（PRT）后的肥大反应。MASTERS试验中约三分之一的参与者正在服用处方他汀类药物。二甲双胍和他汀类药物联合使用可挽救二甲双胍介导的PRT生长反应受损，但对力量没有显著影响。改善的肌纤维生长可能与药物诱导的CD11b+/CD206+ M2样巨噬细胞丰度增加有关。肌肉减少症是衰老过程中的一个重要问题，这项研究确定了这些常用药物之间的潜在相互作用，这可能有助于预防二甲双胍相关的PRT有益效果减弱。ClinicalTrials.gov，NCT02308228，于2014年11月25日注册。
